CO6501139A2 - 11BETA-HYDROXIESTEROID DEHYDROGENASE CYCLIC INHIBITORS 1 - Google Patents

11BETA-HYDROXIESTEROID DEHYDROGENASE CYCLIC INHIBITORS 1

Info

Publication number
CO6501139A2
CO6501139A2 CO11131281A CO11131281A CO6501139A2 CO 6501139 A2 CO6501139 A2 CO 6501139A2 CO 11131281 A CO11131281 A CO 11131281A CO 11131281 A CO11131281 A CO 11131281A CO 6501139 A2 CO6501139 A2 CO 6501139A2
Authority
CO
Colombia
Prior art keywords
11beta
cyclic inhibitors
hydroxiesteroid
dehydrogenase
cortisol
Prior art date
Application number
CO11131281A
Other languages
Spanish (es)
Inventor
Martin Renz
Martin Schuele
Zhenrong Xu
Original Assignee
Vitae Pharmaceuticals Inc
Boheringer Ingelheim Internat Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45478607&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6501139(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/US2009/002653 external-priority patent/WO2009134400A1/en
Priority claimed from PCT/US2009/004261 external-priority patent/WO2010011314A1/en
Application filed by Vitae Pharmaceuticals Inc, Boheringer Ingelheim Internat Gmbh filed Critical Vitae Pharmaceuticals Inc
Publication of CO6501139A2 publication Critical patent/CO6501139A2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Esta invención se refiere a nuevos compuestos de la Fórmula Ik, lm1, lm2, lm5, ln1, ln2, ln5, lo1, lo2, lo5, lp1, Ip3, a sales farmacéuticamente aceptables de los mismos y a composiciones farmacéuticas de los mismos, que son útiles para el tratamiento terapéutico de enfermedades asociadas con la modulación o inhibición de 11ß-HSD1 en mamíferos. La invención también se refiere a composiciones farmacéuticas de los nuevos compuestos y métodos para su uso en la reducción o control de la producción de cortisol en una célula o la inhibición de la conversión de cortisona en cortisol en una célula.This invention relates to new compounds of the Formula Ik, lm1, lm2, lm5, ln1, ln2, ln5, lo1, lo2, lo5, lp1, Ip3, pharmaceutically acceptable salts thereof and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11β-HSD1 in mammals. The invention also relates to pharmaceutical compositions of the new compounds and methods for use in reducing or controlling the production of cortisol in a cell or inhibiting the conversion of cortisone to cortisol in a cell.

CO11131281A 2009-04-30 2011-10-05 11BETA-HYDROXIESTEROID DEHYDROGENASE CYCLIC INHIBITORS 1 CO6501139A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US2009/002653 WO2009134400A1 (en) 2008-05-01 2009-04-30 Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
PCT/US2009/004261 WO2010011314A1 (en) 2008-07-25 2009-07-23 Cyclic inhibitors of 11 beta-hydroxysteroid dehydrogenase 1

Publications (1)

Publication Number Publication Date
CO6501139A2 true CO6501139A2 (en) 2012-08-15

Family

ID=45478607

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11131281A CO6501139A2 (en) 2009-04-30 2011-10-05 11BETA-HYDROXIESTEROID DEHYDROGENASE CYCLIC INHIBITORS 1

Country Status (10)

Country Link
JP (1) JP5784006B2 (en)
AP (1) AP2011005948A0 (en)
CL (1) CL2014001815A1 (en)
CO (1) CO6501139A2 (en)
HK (1) HK1169409A1 (en)
IL (1) IL215249A (en)
MX (1) MX2011011503A (en)
NZ (1) NZ595473A (en)
PE (1) PE20120794A1 (en)
TN (1) TN2010000467A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2393807B1 (en) * 2009-02-04 2013-08-14 Boehringer Ingelheim International GmbH Cyclic inhibitors of 11 -hydroxysteroid dehydrogenase 1

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR067673A1 (en) * 2007-07-26 2009-10-21 Vitae Pharmaceuticals Inc DERIVATIVES OF 1,3 OXAZINAN - 2 - ONA AS CYCLE INHIBITORS OF THE 11 BETA -HYDROXIESTEROID DEHYDROGENASE 1. PHARMACEUTICAL COMPOSITIONS.

Also Published As

Publication number Publication date
AP2011005948A0 (en) 2011-10-31
CL2014001815A1 (en) 2015-02-13
HK1169409A1 (en) 2013-01-25
TN2010000467A1 (en) 2012-05-24
IL215249A0 (en) 2011-12-29
JP5784006B2 (en) 2015-09-24
NZ595473A (en) 2014-01-31
JP2012525440A (en) 2012-10-22
MX2011011503A (en) 2011-11-18
IL215249A (en) 2014-12-31
PE20120794A1 (en) 2012-07-26

Similar Documents

Publication Publication Date Title
UY32591A (en) 11BETA-HYDROXIESTEROID DEHYDROGENASE CYCLE INHIBITORS 1
CL2013000304A1 (en) Compounds derived from prostaglandin e2 inhibitor 2-arylamino-benzimidazoles (mpges-1); pharmaceutical composition that includes them; intermediary compounds; use in the treatment of inflammatory diseases and / or associated conditions, in particular pain.
CL2011002180A1 (en) Compounds derived from benzimidazole, mpges-1 inhibitors; pharmaceutical composition that includes them; and its use in the treatment of inflammatory diseases and pain.
CL2011003266A1 (en) Compounds derived from imidazolidin-2-one, with inhibitory activity of 17alpha-hydroxylase / lyase-c17,20; pharmaceutical composition comprising them; and use in the treatment of inflammation or cancer, among others.
UY31314A1 (en) HETEROCICLIC AMIDAS AND ITS METHODS OF USE-976
ECSP10010615A (en) DERIVATIVES OF BENZOFURANO, BENZOTIOFENO, BENZOTIAZOL AS FXR MODULATORS
UY33616A (en) COMPOUNDS WITH IMIDAZOTRIAZINONA STRUCTURE
NO20092444L (en) Heteroarylamidderivater
CL2009001059A1 (en) Compounds derived from substituted 1,3-oxazin-2-one-3.6, inhibitors of the activity of 11-beta-hydroxysteroid dehydrogenase i; pharmaceutical composition that includes them; Useful in the treatment of diseases such as diabetes mellitus, among others.
BRPI0917017B8 (en) s-nitrosoglutathione reductase pyrrole inhibitors as therapeutic agents
ECSP066717A (en) SUBSTITUTED QUINOLINE COMPOUNDS
CL2008001721A1 (en) Compounds derived from 17-beta-cyano-18 alpha-homo-19-nor-androst-4-eno; presenting gestagenic and antimineralcorticoid activity; pharmaceutical composition; and use in the treatment of pre-peri-and postmenopausal disorders and premenstrual disorders.
ECSP13013048A (en) SPIRO- [1,3] -OXACINES AND SPIRO- [1,4] -OXACEPINS AS INHIBITORS
CR10489A (en) PHENYL-PIRAZOL DERIVATIVES AS LEGANDS OF NON-STEROID GLUCOCORTICOID RECEPTORS
CR11731A (en) COMPOSITIONS AND PROCEDURES FOR PREPARATION AND USE
CR20110599A (en) PHARMACEUTICALLY ACTIVE COMPOSITIONS THAT INCLUDE OXIDATIVE STRESS MODULATORS (OSM), NEW CHEMICAL ENTITIES, COMPOSITIONS AND USES
PA8720801A1 (en) NEW THERAPEUTIC COMBINATIONS FOR THE TREATMENT OF DEPRESSION
CR20110269A (en) WE REACT AS BETA SECRETASA INHIBITORS
CO6321241A2 (en) DERIVED FROM 1,3,4- TIADIAZOL ESPIRO CONDENSED FOR THE INHIBITION OF THE QUINESINA ACTIVITY (KSP)
CL2009001240A1 (en) Compounds derived from l-glutamic acid and l-glutamine labeled with [f-18]; preparation procedure; pharmaceutical composition comprising the compounds and their use as agents in the diagnosis of tumors.
PA8846201A1 (en) DERIVATIVES OF ANILINA-PYRIMIDINE SUBSTITUTED WITH SULFOXIMINE AS INHIBITORS OF CYCLINE-DEPENDENT KINASES (CDK), PRODUCTION AND USE OF THE SAME AS MEDICINAL PRODUCTS
CL2011000341A1 (en) Compounds derived from substituted pyrrolidinone, modulators of ar activity for the inhibition of ntd; preparation procedure; pharmaceutical composition; and use for the treatment of cancer, acne, hirsutism, among others.
CO7151509A2 (en) Difluoro-hexahydro-cyclopentaoxacinyls and difluoro-hexahydro-benzooxacinyls as bace1 inhibitors
CO7131369A2 (en) 5-amino [1,4] thiazines as bace1 inhibitors
CL2009000445A1 (en) Compounds derived from piperidine 1,4 heterocycle substituted, procedure to prepare these compounds, pharmaceutical composition comprising them and their use for pain therapy and the treatment of diseases such as Alzheimer's, schizophrenia, anxiety and depression.

Legal Events

Date Code Title Description
FC Application refused